Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Revenue (2023)

Contineum Therapeutics (CTNM) has 1 years of Revenue data on record, last reported at $50.0 million in Q2 2023.

  • For Q2 2023, Revenue changed N/A year-over-year to $50.0 million; the TTM value through Mar 2024 reached $50.0 million, changed N/A, while the annual FY2023 figure was $50.0 million, N/A changed from the prior year.
  • Revenue reached $50.0 million in Q2 2023 per CTNM's latest filing, up from -$92000.0 in the prior quarter.
  • Across five years, Revenue topped out at $50.0 million in Q2 2023 and bottomed at -$92000.0 in Q1 2023.